Michèle J. Hoffmann

3.3k total citations
100 papers, 2.3k citations indexed

About

Michèle J. Hoffmann is a scholar working on Molecular Biology, Surgery and Oncology. According to data from OpenAlex, Michèle J. Hoffmann has authored 100 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Molecular Biology, 31 papers in Surgery and 27 papers in Oncology. Recurrent topics in Michèle J. Hoffmann's work include Epigenetics and DNA Methylation (42 papers), Bladder and Urothelial Cancer Treatments (30 papers) and Histone Deacetylase Inhibitors Research (20 papers). Michèle J. Hoffmann is often cited by papers focused on Epigenetics and DNA Methylation (42 papers), Bladder and Urothelial Cancer Treatments (30 papers) and Histone Deacetylase Inhibitors Research (20 papers). Michèle J. Hoffmann collaborates with scholars based in Germany, Switzerland and Hungary. Michèle J. Hoffmann's co-authors include Wolfgang A. Schulz, Günter Niegisch, Rainer Engers, Maria Pinkerneil, Mirko Müller, Andrea R. Florl, Margaretha A. Skowron, Tibor Szarvas, Christiane Hader and Volker Jung and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Michèle J. Hoffmann

93 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michèle J. Hoffmann Germany 29 1.7k 536 487 380 280 100 2.3k
Nobuyuki Kikuno Japan 26 1.4k 0.8× 352 0.7× 475 1.0× 291 0.8× 409 1.5× 46 2.1k
Haowen Jiang China 25 1.0k 0.6× 631 1.2× 371 0.8× 410 1.1× 434 1.6× 104 1.8k
Jonathan Krell United Kingdom 29 1.4k 0.8× 1.3k 2.5× 814 1.7× 257 0.7× 278 1.0× 126 2.6k
Masanori Kaneuchi Japan 32 1.2k 0.7× 692 1.3× 642 1.3× 424 1.1× 306 1.1× 92 3.3k
Beihua Kong China 32 1.2k 0.7× 685 1.3× 611 1.3× 311 0.8× 290 1.0× 121 3.1k
Kishore Guda United States 21 880 0.5× 432 0.8× 421 0.9× 301 0.8× 228 0.8× 47 1.6k
Rakesh Singal United States 24 2.4k 1.4× 503 0.9× 565 1.2× 237 0.6× 519 1.9× 50 3.3k
Jian Zhu China 27 1.0k 0.6× 626 1.2× 489 1.0× 179 0.5× 132 0.5× 86 2.0k
Soodabeh Shahidsales Iran 28 1.5k 0.8× 949 1.8× 677 1.4× 196 0.5× 297 1.1× 91 2.5k
Ulla Puistola Finland 34 1.1k 0.6× 731 1.4× 557 1.1× 269 0.7× 201 0.7× 112 2.7k

Countries citing papers authored by Michèle J. Hoffmann

Since Specialization
Citations

This map shows the geographic impact of Michèle J. Hoffmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michèle J. Hoffmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michèle J. Hoffmann more than expected).

Fields of papers citing papers by Michèle J. Hoffmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michèle J. Hoffmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michèle J. Hoffmann. The network helps show where Michèle J. Hoffmann may publish in the future.

Co-authorship network of co-authors of Michèle J. Hoffmann

This figure shows the co-authorship network connecting the top 25 collaborators of Michèle J. Hoffmann. A scholar is included among the top collaborators of Michèle J. Hoffmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michèle J. Hoffmann. Michèle J. Hoffmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Akhoundova, Dilara, et al.. (2025). Prognostic Value of Post-Transplant MRD Negativity in Standard Versus High- and Ultra-High-Risk Multiple Myeloma Patients. Cancers. 17(9). 1565–1565. 1 indexed citations
2.
Jutzi, Jonas S., Jason A. Wampfler, Michèle J. Hoffmann, et al.. (2025). CAR T‐Cell Therapies for Patients With Relapsed and Refractory Aggressive Lymphomas: Real‐World Experiences From a Single Center on the Use of Radiotherapy. Hematological Oncology. 43(5). e70124–e70124.
3.
Hoffmann, Michèle J., Uyen Huynh‐Do, Yara Banz, et al.. (2025). Elranatamab for Relapsed/Refractory Multiple Myeloma With Severe Renal Impairment Requiring Hemodialysis. Hematological Oncology. 43(4). e70120–e70120. 1 indexed citations
4.
Akhoundova, Dilara, et al.. (2025). Adherence to Multidisciplinary Tumor Board Recommendations in Patients with Multiple Myeloma. Cancers. 17(8). 1297–1297.
5.
Petzsch, Patrick, et al.. (2023). Tumorigenic effects of human mesenchymal stromal cells and fibroblasts on bladder cancer cells. Frontiers in Oncology. 13. 1228185–1228185. 4 indexed citations
6.
Bacher, Ulrike, Katja Seipel, Naomi Porret, et al.. (2023). CAR T-Cell Persistence Correlates with Improved Outcome in Patients with B-Cell Lymphoma. International Journal of Molecular Sciences. 24(6). 5688–5688. 40 indexed citations
7.
Bacher, Ulrike, Michèle J. Hoffmann, Urban Novak, et al.. (2023). Evaluation of Bortezomib-BeEAM (2BeEAM) as Chemotherapy Regimen Prior to ASCT in Patients with Mantle Cell Lymphoma. Cancers. 15(7). 2091–2091.
8.
Schulz, Wolfgang A., et al.. (2021). Epigenetic Treatment of Urothelial Carcinoma Cells Sensitizes to Cisplatin Chemotherapy and PARP Inhibitor Treatment. Cancers. 13(6). 1376–1376. 8 indexed citations
9.
10.
Goering, Wolfgang, Tobias Lautwein, Christiane Hader, et al.. (2020). Many Different LINE-1 Retroelements Are Activated in Bladder Cancer. International Journal of Molecular Sciences. 21(24). 9433–9433. 7 indexed citations
11.
Hamacher, Alexandra, Patrick Petzsch, Karl Köhrer, et al.. (2020). Combination of Decitabine and Entinostat Synergistically Inhibits Urothelial Bladder Cancer Cells via Activation of FoxO1. Cancers. 12(2). 337–337. 25 indexed citations
12.
Erichsen, Lars, Hans‐Helge Seifert, Wolfgang A. Schulz, et al.. (2020). Basic Hallmarks of Urothelial Cancer Unleashed in Primary Uroepithelium by Interference with the Epigenetic Master Regulator ODC1. Scientific Reports. 10(1). 3808–3808. 10 indexed citations
13.
Szarvas, Tibor, Michèle J. Hoffmann, Csilla Oláh, et al.. (2020). MMP-7 Serum and Tissue Levels Are Associated with Poor Survival in Platinum-Treated Bladder Cancer Patients. Diagnostics. 11(1). 48–48. 11 indexed citations
14.
Oláh, Csilla, Stephan Tschirdewahn, Michèle J. Hoffmann, et al.. (2020). Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients. Diagnostics. 10(11). 864–864. 8 indexed citations
15.
Lang, Alexander, Christiane Hader, Nicholas Wagner, et al.. (2019). Contingencies of UTX/KDM6A Action in Urothelial Carcinoma. Cancers. 11(4). 481–481. 20 indexed citations
16.
Vasudevan, Ananda Ayyappan Jaguva, Michèle J. Hoffmann, Gereon Poschmann, et al.. (2019). HDAC5 Expression in Urothelial Carcinoma Cell Lines Inhibits Long-Term Proliferation but Can Promote Epithelial-to-Mesenchymal Transition. International Journal of Molecular Sciences. 20(9). 2135–2135. 15 indexed citations
17.
Skowron, Margaretha A., Joep G.H. van Roermund, Andrea Romano, et al.. (2018). Multifaceted Mechanisms of Cisplatin Resistance in Long-Term Treated Urothelial Carcinoma Cell Lines. International Journal of Molecular Sciences. 19(2). 590–590. 34 indexed citations
18.
Skowron, Margaretha A., Günter Niegisch, Philipp Albrecht, et al.. (2017). Various Mechanisms Involve the Nuclear Factor (Erythroid-Derived 2)-Like (NRF2) to Achieve Cytoprotection in Long-Term Cisplatin-Treated Urothelial Carcinoma Cell Lines. International Journal of Molecular Sciences. 18(8). 1680–1680. 14 indexed citations
19.
Lehmann, Sylvain, Michèle J. Hoffmann, Christoph Peter, et al.. (2015). Staurosporine resistance in inflammatory neutrophils is associated with the inhibition of caspase- and proteasome-mediated Mcl-1 degradation. Journal of Leukocyte Biology. 99(1). 163–174. 11 indexed citations
20.
Hoffmann, Michèle J., et al.. (2015). Truncated Isoforms of lncRNA ANRIL Are Overexpressed in Bladder Cancer, But Do Not Contribute to Repression of INK4 Tumor Suppressors. Non-Coding RNA. 1(3). 266–284. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nobuyuki Kikuno Breakdown of academic impact, for papers by Haowen Jiang Breakdown of academic impact, for papers by Jonathan Krell Breakdown of academic impact, for papers by Masanori Kaneuchi Breakdown of academic impact, for papers by Beihua Kong Breakdown of academic impact, for papers by Kishore Guda Breakdown of academic impact, for papers by Rakesh Singal Breakdown of academic impact, for papers by Jian Zhu Breakdown of academic impact, for papers by Soodabeh Shahidsales Breakdown of academic impact, for papers by Ulla Puistola
Rankless by CCL
2026